Literature DB >> 26289505

Nonalcoholic fatty liver disease: Synopsis of current developments.

C A Onyekwere1, A O Ogbera, A A Samaila, B O Balogun, F B Abdulkareem.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) which is defined as the accumulation of fat>5% of liver weight is increasingly becoming an important cause of chronic liver disease. This article tries to chronicle advances that have occurred in the understanding of the pathogenesis, pathology as well as the management of this disease. We have done a Medline search on published work on the subject and reviewed major conference proceedings in the preceding years. The Pathogenesis involves a multi-hit process in which increased accumulation of triglycerides in face of insulin resistance results in increased susceptibility to inflammatory damage mediated by increased expression of inflammatory cytokines and adipokines, oxidative stress and mitochondrial dysfunction, endoplasmic reticulum stress and gut derived endotoxemia. An interplay of multiple metabolic genetic expression and environmental factors however determine which patient with NAFLD will progress from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver cirrhosis. The minimum criteria for diagnosis of NASH are steatosis, ballooning and lobular inflammation; fibrosis is not required. The NASH Clinical Research Network (CRN), histological scoring system is used to grade and stage the disease for standardization. The management of NAFLD consists of treating liver disease as well as associated metabolic co-morbidities such as obesity, hyperlipidaemia, insulin resistance and type 2 diabetes mellitus (T2DM). Patient education is important as their insight and commitment is pivotal, and lifestyle modification is the first line of treatment. Improvement in liver histology in non-diabetic NASH patients has been reported with use of Vitamin E. Other liver-related therapies under investigations include pentoxyfiylins, Caspar inhibitors, Resveratrol as well as probiotics. The prognosis (both overall and liver-related mortality) for simple steatosis is not different from that of the general population however.

Entities:  

Mesh:

Year:  2015        PMID: 26289505     DOI: 10.4103/1119-3077.163288

Source DB:  PubMed          Journal:  Niger J Clin Pract            Impact factor:   0.968


  10 in total

1.  Protective effects of Gastrodia elata Blume on acetaminophen-induced liver and kidney toxicity in rats.

Authors:  Pu Reum Seok; Jung Hoan Kim; Hye Ri Kwon; Jin Sun Heo; Jong Ryeol Choi; Jae-Ho Shin
Journal:  Food Sci Biotechnol       Date:  2018-05-15       Impact factor: 2.391

2.  Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease.

Authors:  Andrew M Jobbins; Nejc Haberman; Natalia Artigas; Christopher Amourda; Helen A B Paterson; Sijia Yu; Samuel J I Blackford; Alex Montoya; Marian Dore; Yi-Fang Wang; Alessandro Sardini; Inês Cebola; Johannes Zuber; Sheikh Tamir Rashid; Boris Lenhard; Santiago Vernia
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

3.  Resveratrol alleviates FFA and CCl4 induced apoptosis in HepG2 cells via restoring endoplasmic reticulum stress.

Authors:  Fenghua Li; Yang Yang; Lili Yang; Kai Wang; Xing Zhang; Yunlong Zong; Yixin Ding; Changhong Wang; Li Zhang; Guang Ji
Journal:  Oncotarget       Date:  2017-07-04

Review 4.  The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease.

Authors:  Magdalena Świderska; Jerzy Jaroszewicz; Agnieszka Stawicka; Anna Parfieniuk-Kowerda; Adrian Chabowski; Robert Flisiak
Journal:  Clin Exp Hepatol       Date:  2017-06-21

5.  FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.

Authors:  Audrey Coilly; Christophe Desterke; Catherine Guettier; Didier Samuel; Franck Chiappini
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

6.  HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters.

Authors:  Muhammad Masroor; Zeba Haque
Journal:  J Clin Transl Hepatol       Date:  2021-01-02

7.  Cholecystectomy does not worsen progression or outcomes in non-alcoholic fatty liver disease.

Authors:  Donny Kakati; Ujjwal Kumar; Kirk Russ; Mohamed Shoreibah; Yong-Fang Kuo; Bradford Jackson; Ashwani K Singal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

Review 8.  The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases.

Authors:  Siwen Zhang; Xiaokun Gang; Shuo Yang; Mengzhao Cui; Lin Sun; Zhuo Li; Guixia Wang
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

9.  Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway.

Authors:  Xiaobo Gao; Shun Guo; Song Zhang; An Liu; Lei Shi; Yan Zhang
Journal:  J Transl Med       Date:  2018-11-20       Impact factor: 5.531

Review 10.  Obesity and nonalcoholic fatty liver disease: current perspectives.

Authors:  Raiya Sarwar; Nicholas Pierce; Sean Koppe
Journal:  Diabetes Metab Syndr Obes       Date:  2018-09-25       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.